Oncofetal TRIM71 Drives Liver Cancer Carcinogenesis Through Remodeling CEBPA-mediated Serine/glycine Metabolism

Overview

Journal Theranostics

Date 2024 Sep 13

PMID 39267787

Authors

Ying Su

Ziteng Li

Qin Li

Xinyi Guo

Hena Zhang

Yan Li

Zhiqiang Meng

Shenglin Huang

Zhixiang Hu

Affiliations

Soon will be listed here.

Abstract

Tumor cells remodel transcriptome to construct an ecosystem with stemness features, which maintains tumor growth and highly malignant characteristics. However, the core regulatory factors involved in this process still need to be further discovered. Single cell RNA-sequncing (scRNA-seq) and bulk RNA-sequencing profiles derived from fetal liver, normal liver, liver tumors, and their adjacent samples were collected to analyze the ecosystem of liver cancer. Mouse models were established to identify molecular functions of oncofetal-related oncogenes using hydrodynamic tail vein injection. We found that liver cancer rebuilt oncofetal ecosystem to maintain malignant features. Interestingly, we identified a group of RNA-binding proteins (RBPs) that were highly overexpressed with oncofetal features. Among them, TRIM71 was specifically expressed in liver cancers and was associated with poor outcomes. TRIM71 drove the carcinogenesis of hepatocellular carcinoma (HCC), and knockdown of TRIM71 significantly abolished liver cancer cell proliferation. Mechanistically, TRIM71 formed a protein complex with IGF2BP1, bound to and stabilized the mRNA of CEBPA in an m6A-dependent manner, enhance the serine/glycine metabolic pathway, and ultimately promoted liver cancer progression. Furthermore, we identified that all-trans-retinoic acid (ATRA) combined with e1A binding protein p300 (EP300) inhibitor A-485 repressed TRIM71, attenuated glycine/serine metabolism, and inhibited liver cancer cell proliferation with high TRIM71 levels. We demonstrated the oncofetal status in liver cancer and highlighted the crucial role of TRIM71 and provided potential therapeutic strategies and liver cancer-specific biomarker for liver cancer patients.

References

Kozono S, Lin Y, Seo H, Pinch B, Lian X, Qiu C . Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018; 9(1):3069. PMC: 6085299. DOI: 10.1038/s41467-018-05402-2. View

Wang K, Luo L, Fu S, Wang M, Wang Z, Dong L . PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat Commun. 2023; 14(1):1011. PMC: 9950448. DOI: 10.1038/s41467-023-36708-5. View

. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017; 169(7):1327-1341.e23. PMC: 5680778. DOI: 10.1016/j.cell.2017.05.046. View

Zhang X, Zhu X, Zhong Z, Du J, Fang G, Cui X . Small Molecule-Induced Differentiation As a Potential Therapy for Liver Cancer. Adv Sci (Weinh). 2022; 9(15):e2103619. PMC: 9131429. DOI: 10.1002/advs.202103619. View

Foster D, Chang H, Haswell J, Gregory R, Slack F . TRIM71 binds to IMP1 and is capable of positive and negative regulation of target RNAs. Cell Cycle. 2020; 19(18):2314-2326. PMC: 7513864. DOI: 10.1080/15384101.2020.1804232. View

Zhu T, Hong L, Ling Z . Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023; 11(1):62. PMC: 10245617. DOI: 10.1186/s40364-023-00499-0. View

Avellino R, Delwel R . Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation. Blood. 2017; 129(15):2083-2091. DOI: 10.1182/blood-2016-09-687822. View

Worringer K, Rand T, Hayashi Y, Sami S, Takahashi K, Tanabe K . The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell. 2013; 14(1):40-52. PMC: 3982312. DOI: 10.1016/j.stem.2013.11.001. View

Nguyen L, Robinton D, Seligson M, Wu L, Li L, Rakheja D . Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell. 2014; 26(2):248-61. PMC: 4145706. DOI: 10.1016/j.ccr.2014.06.018. View

10.

He P, He C . m A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021; 40(3):e105977. PMC: 7849164. DOI: 10.15252/embj.2020105977. View

11.

Chen Q, Yang B, Liu X, Zhang X, Zhang L, Liu T . Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022; 12(11):4935-4948. PMC: 9274749. DOI: 10.7150/thno.73223. View

12.

Mehta M, Raguraman R, Ramesh R, Munshi A . RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer. Adv Drug Deliv Rev. 2022; 191:114569. PMC: 10411638. DOI: 10.1016/j.addr.2022.114569. View

13.

Sharma A, Seow J, Dutertre C, Pai R, Bleriot C, Mishra A . Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020; 183(2):377-394.e21. DOI: 10.1016/j.cell.2020.08.040. View

14.

Ma X, Li C, Sun L, Huang D, Li T, He X . Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1. Nat Commun. 2014; 5:5212. DOI: 10.1038/ncomms6212. View

15.

Zhang Y, Guan D, Shi J, Gao H, Li J, Zhao J . All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. J Hepatol. 2013; 59(6):1255-63. DOI: 10.1016/j.jhep.2013.07.009. View

16.

Gandhi M, Gross M, Holler J, Coggins S, Patil N, Leupold J . The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun. 2020; 11(1):3214. PMC: 7316977. DOI: 10.1038/s41467-020-17007-9. View

17.

Li W, Deng X, Chen J . RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol. 2022; 86(Pt 2):664-677. PMC: 9526761. DOI: 10.1016/j.semcancer.2022.03.025. View

18.

Li Z, Zhang H, Li Q, Feng W, Jia X, Zhou R . GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases. Sci Data. 2023; 10(1):376. PMC: 10257690. DOI: 10.1038/s41597-023-02257-1. View

19.

You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S . Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1):196. PMC: 10172373. DOI: 10.1038/s41392-023-01442-3. View

20.

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View